fda sued over tirzepatide approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Republican Administration Maintains Exclusivity Stance

Nausea (44%), diarrhoea (30%), vomiting (24%), and constipation (24%)

Pharmacologically, KLOW is mostly given as small subcutaneous injections in research studies, with typical vials containing 50 to 100 milligrams, split into daily or every-other-day doses over 410 week cycles

Landmark trials including STEP 1 and STEP 2 (published in *New England Journal of Medicine*) demonstrated superior weight loss and lower dropout rates with stepwise escalation versus fixed-dose approaches

A number of GLP-1RAs are available for subcutaneous injection which differ in their molecular structure, size, half-life, and dosing interval (Fig